Brind.

Sanofi provided a $7 million milestone payment related to an agreement for upgrading a therapeutic development platform.

4 reports, 4 independent Updated Aug 6

Gone quiet Reached 4 outlets in its first 24 hours

Reports: 4
Developments: 4
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Sanofi provided a $7 million milestone payment related to an agreement for upgrading a therapeutic development platform.

Who's involved

What this event is mainly about

Sanofi Recursion (United States)BAYER

How it developed

Newest first. Tap a step to see who reported it.

Aug 6Recursion generates revenue from partnerships with Sanofi, Bayer, and Merck, while stock falls.1 source
- Motley Fool
Aug 6Sanofi paid $7M milestone payment for therapeutic development platform upgrade.1 source
- Zacks
Aug 5Recursion and Sanofi announced a new discovery milestone in their collaboration.1 source
- GlobeNewswire
Jul 10Collaboration project timing updates and Morgan Stanley rating for pharma stocks.1 source
- Insider Monkey

Keep exploring

The entities involved

Sanofi
company in Milan, Italy

Nothing else this week.
Recursion (United States)
company in Salt Lake City, United States
- Recursion (United States) disclosed insider trading via required filings with the SEC on June 6, 2026.Sun 17:12
- Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.Sun 05:14
BAYER
company in Prague, Czechia
- Bayer acquired Monsanto and its Roundup product line. The company now faces lawsuits regarding the product's liability.Sun 23:14
- Bayer is supplying canola feedstock to Neste to jointly scale winter canola for biofuels.Sun 16:16

Related events

Sanofi collaborated on original report with US entities.Aug 27

Coverage

Newest first; wire copies grouped

Aug 6Motley FoolWhy Recursion Pharmaceuticals Stock Tanked on Tuesday Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. 10 sto
Aug 6ZacksRXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down Recursion Pharmaceuticals RXRX reported a loss of 41 cents per share in the second quarter of 2025, wider than the Zacks Consensus Esti
Aug 5GlobeNewswireRecursion Reports Second Quarter 2025 Financial Results and Provides Business Update Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on pati
Jul 10Insider MonkeyMorgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 11 Best Mid-cap Healthcare Stocks to